Theriva Biologics, Inc. TOVX
0.18 USD 0.00 (-1.09%)
At closeNov 3, 2026, 4:00 PM EST
0.18 0.00 +1.15%
After hours · Nov 3, 4:00 PM ET
0.1775 Day range 0.2013
0.14 52-week range 0.49
- YTD
- -13.33%
- 1 year
- -44.85%
News
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
globenewswire.com Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc. – Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along with low single-digit royalties on net product sales – –…
globenewswire.com Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine - Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer - - Data…
globenewswire.com Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2026 - Se ha administrado la primera dosis a los pacientes en el estudio clínico VIRAGE2 de Fase IIa, que evalúa la administración con mayor frecuencia de VCN-01 (zabilugene almadenorepvec), cuyo objetivo…
benzinga.com Theriva Biologics Q2 EPS $(0.07) Misses $(0.05) Estimate Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 96.37 percent increase over losses of…
globenewswire.com Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results – First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in…
globenewswire.com Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in metastatic pancreatic ductal adenocarcinoma (PDAC) -
benzinga.com Theriva Biologics Receives Spanish Agency Of Medicines And Medical Devices Authorization To Initiate Its VIRAGE2 Clinical Trial Trial is entitled "A Phase IIa, single-arm, single-center, open-label, proof-of-concept trial evaluating increased frequency dosing of zabilugene almadenorepvec (VCN-01) in combination with
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion. Bluejay…
globenewswire.com Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial - - Study builds on positive clinical data from the recent…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Theriva Biologics Announces Publication Of Clinical, Translational Results From VCN-01's Phase 1 Clinical Trial In Head & Neck Squamous Cell Carcinoma In Clinical Cancer Research Journal – Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor…
globenewswire.com Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research - Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head and Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor…
benzinga.com Theriva Biologics Q1 EPS $(0.05), Inline Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 96.77 percent increase over losses of $(1.55) per share from the same…
globenewswire.com Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results – Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Amazon Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Amazon Inc (NASDAQ: AMZN) rose in pre-market trading after announcing a strategic collaboration with Anthropic to spend $100B on AWS.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Why Is Theriva Stock Gaining Monday? Theriva Biologics Inc. shares are trading higher Monday after announcing upcoming poster on VIRAGE phase 2b VCN-01 pancreatic cancer trial.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $17 billion. Shares jump 20.2% to $493.01.
globenewswire.com Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026 - Los análisis de la respuesta tumoral, los biomarcadores y los subgrupos del ensayo clínico VIRAGE de Fase 2b respaldan el mecanismo de acción inmunomediado de VCN-01 y demuestran una mejora en los…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Theriva Biologics' VCN-01 Shows Immune-Mediated Activity And Improved Outcomes Across Subgroups In Phase 2b Pancreatic Cancer Trial At AACR 2026 - Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients…
globenewswire.com Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting - Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Maxim Group Upgrades Theriva Biologics to Buy, Announces $1 Price Target Maxim Group analyst Jason McCarthy upgrades Theriva Biologics (AMEX:TOVX) from Hold to Buy and announces $1 price target.
- benzinga.com Theriva Biologics Announces It Receives FDA's General Agreement For Phase 3 Clinical Study Of VCN-01 To Treat Metastatic Pancreatic Adenocarcinoma Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the…
globenewswire.com Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma - Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC - -…
globenewswire.com Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2025 - Avances en el desarrollo clínico del VCN-01 para el adenocarcinoma ductal pancreático y el retinoblastoma - - Concesión de la licencia de SYN-020 a Rasayana Therapeutics para su desarrollo en…- benzinga.com Theriva Biologics Q4 EPS $(0.12) Beats $(0.50) Estimate Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.50) by 76.2 percent. This is a 92.52 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Why Etsy Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Theriva Biologics To Present Data From VCN-01 Retinoblastoma Phase 1 Clinical Trial At APAO 2026 - Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of…
defenseworld.net Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Down 4.9% – Time to Sell? Theriva Biologics, Inc. (NYSEAMERICAN:TOVX - Get Free Report)'s stock price traded down 4.9% on Wednesday. The stock traded as low as $0.1926 and last traded at $0.2007. 2,809,196 shares were traded…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
feeds.benzinga.com Why Is Theriva Biologics Stock Gaining Monday? Theriva Biologics stock rose on Monday as it received positive Scientific Advice from CHMP for a Phase 3 trial of VCN-01 for PDAC treatment.
benzinga.com Why Is Theriva Biologics Stock Gaining Monday? Theriva Biologics stock rose on Monday as it received positive Scientific Advice from CHMP for a Phase 3 trial of VCN-01 for PDAC treatment.
globenewswire.com Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) - EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC , including sample…
defenseworld.net Theriva Biologics (NYSEAMERICAN:TOVX) Trading 5.2% Higher – Here’s Why Theriva Biologics, Inc. (NYSEAMERICAN:TOVX - Get Free Report)'s share price was up 5.2% during mid-day trading on Tuesday. The stock traded as high as $0.2187 and last traded at $0.2029.…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session